JP2022512649A5 - - Google Patents

Info

Publication number
JP2022512649A5
JP2022512649A5 JP2021519642A JP2021519642A JP2022512649A5 JP 2022512649 A5 JP2022512649 A5 JP 2022512649A5 JP 2021519642 A JP2021519642 A JP 2021519642A JP 2021519642 A JP2021519642 A JP 2021519642A JP 2022512649 A5 JP2022512649 A5 JP 2022512649A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cdr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512649A (ja
JP7462621B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/055084 external-priority patent/WO2019074973A2/en
Application filed filed Critical
Priority claimed from PCT/US2019/055232 external-priority patent/WO2020076853A1/en
Publication of JP2022512649A publication Critical patent/JP2022512649A/ja
Publication of JP2022512649A5 publication Critical patent/JP2022512649A5/ja
Application granted granted Critical
Publication of JP7462621B2 publication Critical patent/JP7462621B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519642A 2018-10-09 2019-10-08 三重特異性抗cd38、抗cd28、および抗cd3結合タンパク質ならびにウイルス感染を処置するための使用方法 Active JP7462621B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
PCT/US2018/055084 WO2019074973A2 (en) 2017-10-10 2018-10-09 ANTI-CD38 ANTIBODIES AND METHODS OF USE
USPCT/US2018/055084 2018-10-09
US201962831608P 2019-04-09 2019-04-09
US201962831572P 2019-04-09 2019-04-09
US62/831,608 2019-04-09
US62/831,572 2019-04-09
EP19306097 2019-09-11
EP19306097.7 2019-09-11
PCT/US2019/055232 WO2020076853A1 (en) 2018-10-09 2019-10-08 Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection

Publications (3)

Publication Number Publication Date
JP2022512649A JP2022512649A (ja) 2022-02-07
JP2022512649A5 true JP2022512649A5 (cg-RX-API-DMAC7.html) 2022-10-17
JP7462621B2 JP7462621B2 (ja) 2024-04-05

Family

ID=70165121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519642A Active JP7462621B2 (ja) 2018-10-09 2019-10-08 三重特異性抗cd38、抗cd28、および抗cd3結合タンパク質ならびにウイルス感染を処置するための使用方法

Country Status (15)

Country Link
US (2) US11530268B2 (cg-RX-API-DMAC7.html)
EP (1) EP3864043A1 (cg-RX-API-DMAC7.html)
JP (1) JP7462621B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210075129A (cg-RX-API-DMAC7.html)
CN (1) CN113166254A (cg-RX-API-DMAC7.html)
AU (1) AU2019357467A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006558A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115679A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004534A2 (cg-RX-API-DMAC7.html)
IL (1) IL282126A (cg-RX-API-DMAC7.html)
MX (1) MX2021004147A (cg-RX-API-DMAC7.html)
SG (1) SG11202103478RA (cg-RX-API-DMAC7.html)
TW (1) TWI856979B (cg-RX-API-DMAC7.html)
WO (1) WO2020076853A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102223B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
AR103488A1 (es) * 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
ES2894304T3 (es) 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
MY192090A (en) 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TWI856979B (zh) 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗cd38、抗cd28和抗cd3結合蛋白和用於治療病毒感染的使用方法
JP7664175B2 (ja) * 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
MX2022004881A (es) 2019-10-25 2022-05-16 Sanofi Sa Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas.
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses
KR20230151513A (ko) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250144193A1 (en) * 2022-02-19 2025-05-08 Salvitus, Inc. Probiotic vaccines and related methods of use
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2023246911A1 (zh) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
CN118667026A (zh) 2023-03-15 2024-09-20 三生国健药业(上海)股份有限公司 抗muc17*cd3*cd28三特异性抗体
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN121586731A (zh) 2023-07-31 2026-02-27 赛诺菲 抗cd38 t细胞接合器在治疗外周t细胞淋巴瘤中的方法和用途
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN121511263A (zh) * 2024-05-27 2026-02-10 杭州阿诺生物医药科技有限公司 一种多功能融合多肽

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN112225798B (zh) 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
CN104080805B (zh) 2011-11-07 2017-02-22 美国政府健康及人类服务部 gp41中和性抗体及其用途
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
US20140213772A1 (en) 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
CN108264557B (zh) * 2016-12-30 2021-08-24 惠和生物技术(上海)有限公司 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
TWI856979B (zh) 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗cd38、抗cd28和抗cd3結合蛋白和用於治療病毒感染的使用方法
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP7664175B2 (ja) * 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用

Similar Documents

Publication Publication Date Title
JP2023085476A5 (cg-RX-API-DMAC7.html)
JP7462621B2 (ja) 三重特異性抗cd38、抗cd28、および抗cd3結合タンパク質ならびにウイルス感染を処置するための使用方法
JP2018537966A5 (cg-RX-API-DMAC7.html)
IL258822B2 (en) Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection
JP2020511947A5 (cg-RX-API-DMAC7.html)
JP2023548045A5 (cg-RX-API-DMAC7.html)
IL272747B2 (en) Bispecific antibodies 1 + 2
JP2019517539A5 (cg-RX-API-DMAC7.html)
JP2018533371A5 (cg-RX-API-DMAC7.html)
JP2020536543A5 (cg-RX-API-DMAC7.html)
JP2020521452A5 (cg-RX-API-DMAC7.html)
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
JP2018522541A5 (cg-RX-API-DMAC7.html)
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JP2018526981A5 (cg-RX-API-DMAC7.html)
JP2020529410A5 (cg-RX-API-DMAC7.html)
JP2019502712A5 (cg-RX-API-DMAC7.html)
JP2017537896A5 (cg-RX-API-DMAC7.html)
JP2017534646A5 (cg-RX-API-DMAC7.html)
JP2023511376A5 (cg-RX-API-DMAC7.html)
JP2023532129A5 (cg-RX-API-DMAC7.html)
JP2024086870A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2019537449A5 (cg-RX-API-DMAC7.html)
US20220144956A1 (en) HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII